Emilio Lucia
Overview
Explore the profile of Emilio Lucia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spessotto P, Clemente N, Mongiat M, Capuano A, Baldassarre G, Polesel J, et al.
Int J Gynecol Cancer
. 2025 Feb;
35(2):101626.
PMID: 39964817
Objective: Probe-based confocal laser endomicroscopy (pCLE) is a novel real-time imaging technique that is potentially useful for accurately distinguishing between normal and cancerous tissues. The aim of this study was...
2.
Nespolo A, Stefenatti L, Pellarin I, Gambelli A, Rampioni Vinciguerra G, Karimbayli J, et al.
Sci Adv
. 2024 Nov;
10(46):eadp6567.
PMID: 39536107
PARP inhibitors (PARPi) represent a game-changing treatment for patients with ovarian cancer with tumors deficient for the homologous recombination (HR) pathway treated with platinum (Pt)-based therapy. PARPi exert their cytotoxic...
3.
Gambelli A, Nespolo A, Rampioni Vinciguerra G, Pivetta E, Pellarin I, Nicoloso M, et al.
EMBO Mol Med
. 2024 Jul;
16(8):1981.
PMID: 38997596
No abstract available.
4.
Gambelli A, Nespolo A, Rampioni Vinciguerra G, Pivetta E, Pellarin I, Nicoloso M, et al.
EMBO Mol Med
. 2024 Apr;
16(5):1162-1192.
PMID: 38658801
Platinum (PT)-resistant Epithelial Ovarian Cancer (EOC) grows as a metastatic disease, disseminating in the abdomen and pelvis. Very few options are available for PT-resistant EOC patients, and little is known...
5.
Bartoletti M, Giorda G, Viel A, Fornasarig M, Zdjelar A, Segatto E, et al.
Curr Oncol
. 2022 Jul;
29(8):5209-5212.
PMID: 35892982
Until recently, effective therapies for advanced endometrial cancer progressing to a platinum-based combination were lacking. In this setting, immunotherapy with anti PD-1/PDL-1 monoclonal antibodies is rising as a new paradigm...
6.
Viotto D, Russo F, Anania I, Segatto I, Rampioni Vinciguerra G, DallAcqua A, et al.
J Pathol
. 2020 Nov;
253(2):234-245.
PMID: 33140857
The CDKN1B gene, encoding for the CDK inhibitor p27 , is mutated in defined human cancer subtypes, including breast, prostate carcinomas and small intestine neuroendocrine tumors. Lessons learned from small...
7.
Mandato V, Torricelli F, Palomba S, Uccella S, Pirillo D, Ciarlini G, et al.
Am J Clin Oncol
. 2019 Apr;
42(5):472-480.
PMID: 30973371
Objectives: The objectives of this study were to evaluate whether the international recommendations on the management of uterine papillary serous carcinoma arising in a polyp are uniformly followed in Italian...
8.
Clemente N, Alessandrini L, Rupolo M, Bulian P, Lucia E, Canzonieri V, et al.
Medicine (Baltimore)
. 2016 Mar;
95(10):e3041.
PMID: 26962826
The aim of this study was to add a new case of primary non-Hodgkin's malignant lymphoma of the vulva to the literature and to review the current literature.We searched the...
9.
Zucchi E, Fornasarig M, Martella L, Maiero S, Lucia E, Borsatti E, et al.
Support Care Cancer
. 2016 Feb;
24(7):2877-82.
PMID: 26838026
Purpose: The purpose of this study was to evaluate patient-centered outcomes of decompressive percutaneous endoscopic gastrostomy (dPEG) in patients with malignant bowel obstruction due to advanced gynecological and gastroenteric malignancies....
10.
Garziera M, Montico M, Bidoli E, Scalone S, Sorio R, Giorda G, et al.
PLoS One
. 2015 Oct;
10(10):e0140351.
PMID: 26451959
Objective: Serum p53 autoantibodies (p53-AAbs) are the product of an endogenous immune response against p53 overexpression driven by the ovarian tumour. The p53-AAbs are detectable only in a subset of...